TYR and melanoma: Additional tumor-associated antigen (TAAs) derived HLA ligands are frequently identified by MS, such as “normal” (wild-type) proteins overexpressed or restricted to tumors (e.g., MelanA, Tyrosinase, PMEL in melanoma; NY-ESO in multiple cancer types).